Consideration of stratification in confirmatory trials with time-to-event endpoint
- PMID: 38215875
- DOI: 10.1016/j.cct.2024.107434
Consideration of stratification in confirmatory trials with time-to-event endpoint
Abstract
Stratification in randomization and analysis are widely employed to balance treatment groups in clinical trials. However, the potential power loss due to under-stratification or over-stratification has not been thoroughly evaluated in the typical setting of confirmatory clinical trials. In cases where there are too many strata and some have small sample sizes or a small number of events, it is common practice to combine these small strata during analysis. However, there is a lack of guidance on how those small strata should be combined. This paper presents extensive simulation studies to evaluate the impact of under-stratification or over-stratification on the power of survival analysis and the estimate of hazard ratio using stratified log-rank test and Cox PH model, respectively. The difference in power between stratified and unstratified log-rank tests is also investigated under different scenarios. Our results suggest that failing to consider prognostic stratification factors with strong effects, and/or accounting for non-prognostic factors such as noise and predictive factors, may reduce the power of the stratified log-rank test. Additionally, methods of combining small strata are explored and compared.
Keywords: Stratification; Stratified analysis; Time-to-event.
Copyright © 2024 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Similar articles
-
Evaluating the impact of stratification on the power and cross-arm balance of randomized phase 2 clinical trials.Clin Trials. 2025 Jun;22(3):361-366. doi: 10.1177/17407745241304065. Epub 2025 Jan 15. Clin Trials. 2025. PMID: 39815460 Free PMC article.
-
Hazard ratio inference in stratified clinical trials with time-to-event endpoints and limited sample size.Pharm Stat. 2019 May;18(3):366-376. doi: 10.1002/pst.1928. Epub 2019 Jan 31. Pharm Stat. 2019. PMID: 30706642
-
Designing clinical trials with (restricted) mean survival time endpoint: Practical considerations.Clin Trials. 2020 Jun;17(3):285-294. doi: 10.1177/1740774520905563. Epub 2020 Feb 17. Clin Trials. 2020. PMID: 32063031
-
Are non-constant rates and non-proportional treatment effects accounted for in the design and analysis of randomised controlled trials? A review of current practice.BMC Med Res Methodol. 2019 May 16;19(1):103. doi: 10.1186/s12874-019-0749-1. BMC Med Res Methodol. 2019. PMID: 31096924 Free PMC article. Review.
-
Balancing Events, Not Patients, Maximizes Power of the Logrank Test: And Other Insights on Unequal Randomization in Survival Trials.Stat Med. 2025 May;44(10-12):e70101. doi: 10.1002/sim.70101. Stat Med. 2025. PMID: 40384620 Review.
MeSH terms
LinkOut - more resources
Full Text Sources